Home/Pipeline/Diabetes Research

Diabetes Research

Diabetes

ResearchActive

Key Facts

Indication

Diabetes

Phase

Research

Status

Active

Company

Evidation Health

About Evidation Health

Evidation Health operates a leading real-world data (RWD) and patient engagement platform that bridges the gap between life sciences research and individuals in their everyday lives. Founded in 2012, the company has established direct connections with over 5 million individuals, enabling the generation of continuous, multimodal data streams—including wearables, patient-reported outcomes, EHR, and molecular data—for research and commercial applications. Its core business model involves licensing its platform to top life sciences companies, healthcare organizations, and government agencies to identify, engage, and retain patient cohorts for long-term studies, thereby accelerating evidence generation and improving health outcomes.

View full company profile

Therapeutic Areas

Cardiovascular Neurology Metabolic Disorders General Wellness

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
Oral Insulin	Premas Biotech	Phase 3	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active
Glucose-Responsive Insulin Receptor Agonist	Protomer Technologies	Pre-clinical (integrated into Lilly pipeline)	Active